Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues

被引:35
|
作者
Hosokawa, Yuko [1 ,2 ,3 ]
Masaki, Noritaka [2 ,3 ]
Takei, Shiro [2 ,3 ]
Horikawa, Makoto [2 ,3 ]
Matsushita, Shoko [2 ,3 ]
Sugiyama, Eiji [2 ,3 ]
Ogura, Hiroyuki [1 ]
Shiiya, Norihiko [1 ]
Setou, Mitsutoshi [2 ,3 ,4 ,5 ,6 ]
机构
[1] Hamamatsu Univ, Sch Med, Dept Surg 1, Higashi Ku, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ, Sch Med, Int Mass Imaging Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ, Sch Med, Dept Cellular & Mol Anat, Higashi Ku, Hamamatsu, Shizuoka, Japan
[4] Preeminent Med Photon Educ & Res Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[5] Univ Hong Kong, Dept Anat, 6-F,William MW Mong Block,Sassoon Rd, Pokfulam, Hong Kong, Peoples R China
[6] RIKEN, Ctr Mol Imaging Sci, Chuo Ku, Kobe, Hyogo, Japan
来源
PLOS ONE | 2017年 / 12卷 / 08期
关键词
MASS-SPECTROMETRY; SURVIVAL;
D O I
10.1371/journal.pone.0183724
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Triple-negative breast cancer (TNBC) is one of the breast cancer subtype that displays a high risk of early recurrence and short overall survival. Improvement of the prognosis of patients with TNBC requires identifying a predictive factor of recurrence, which would make it possible to provide beneficial personalized treatment. However, no clinically reliable predictive factor is currently known. In this study, we investigated the predictive factor of recurrence in TNBC using matrix-assisted laser desorption/ionization-imaging mass spectrometry for lipid profiling of breast cancer specimens obtained from three and six patients with recurrent and non-recurrent TNBC, respectively. The signal for phosphatidylcholine (PC) (32:1) at m/z 732.5 was significantly higher in the recurrence group compared to the non-recurrence group (P = 0.024). PC (32:1) was more abundant in the cancer epithelial area than it was in the surrounding stroma, suggesting that abnormal lipid metabolism was associated with malignant transformation. Our results indicate PC (32:1) as a candidate predictive factor of TNBC recurrence. A future prospective study investigating whether personalized therapy based on PC (32:1) intensity improves the prognosis of patients with TNBC is recommended.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Spatial Analysis of the Tumor Microenvironment and Gene Expression in LSD1-expressing Triple-negative Breast Cancer (TNBC)
    Iqbal, Jabed
    Yeong, Joe
    Lee, Dong Yeul
    Hong, Jing Han
    LABORATORY INVESTIGATION, 2024, 104 (03) : S177 - S179
  • [22] Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)
    Scott, M.
    Scorer, P.
    Barker, C.
    Al-Masri, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Prognostic Assessment of Stromal and Non-Stromal Tumor-Infiltrating Lymphocytes (TILs) in Triple-Negative Breast Cancer (TNBC)
    Ghosh, Toshi
    Goetz, Matthew
    Leon-Ferre, Roberto A.
    Liu, Heshan
    Polley, Mei-Yin C.
    Ingle, James
    Cafourek, Victoria L.
    Hillman, David W.
    Carter, Jodi
    Visscher, Daniel
    LABORATORY INVESTIGATION, 2018, 98 : 61 - 62
  • [24] Is docetaxel (D) less efficient than anthracycline-based chemotherapy (A) in triple-negative breast cancer (TNBC) treated in neoadjuvant setting?
    Simon, Laurence
    Belletier, Christine
    Rodier, Jean-Francois
    Weitbruch, Delphine
    Velten, Michel
    Wilt, Marc
    Ghnassia, Jean-Pierre
    Petit, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Prognostic Assessment of Stromal and Non-Stromal Tumor-Infiltrating Lymphocytes (TILs) in Triple-Negative Breast Cancer (TNBC)
    Ghosh, Toshi
    Goetz, Matthew
    Leon-Ferre, Roberto A.
    Liu, Heshan
    Polley, Mei-Yin C.
    Ingle, James
    Cafourek, Victoria L.
    Hillman, David W.
    Carter, Jodi
    Visscher, Daniel
    MODERN PATHOLOGY, 2018, 31 : 61 - 62
  • [26] Immunogenic chemotherapy synergize PD-1 blockade by enhancing dendritic cells infiltration in triple-negative breast cancer (TNBC)
    Yuan, Xiangliang
    Xiao, Yi
    Kuo, Wenling
    Yu, Dihua
    CANCER RESEARCH, 2016, 76
  • [27] Development of novel combination therapy of IGF-1R/InsR and MEK inhibitors in triple-negative breast cancer (TNBC)
    Kai, K.
    Kondo, K.
    Bartholomeusz, C.
    Valero, V.
    Hortobagyi, G. N.
    Ueno, N. T.
    CANCER RESEARCH, 2013, 73
  • [28] Higher elastography strain ratio (ESR) predicts less distant recurrence in triple-negative breast cancer (TNBC): Softer tumor environment is deleterious?
    Wang, H.
    Zhu, Y.
    Shen, K.
    Zhu, S.
    BREAST, 2025, 80
  • [29] Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research
    Wang, Li
    Liu, Dequan
    Wu, Xingrao
    Zeng, Yueqin
    Li, Lan
    Hou, Yu
    Li, Wenhui
    Liu, Zhijie
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (10) : 6603 - 6612
  • [30] Ferroptosis Inducers Upregulate PD-L1 in Recurrent Triple-Negative Breast Cancer
    Desterke, Christophe
    Xiang, Yao
    Elhage, Rima
    Duruel, Clemence
    Chang, Yunhua
    Hamai, Ahmed
    CANCERS, 2024, 16 (01)